News
08-20-2010, 12:02 AM
SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.
More... (http://www.news-medical.net/news/20100820/SRI-and-Taiho-collaborate-to-advance-clinical-development-of-TAS-108-breast-cancer-program.aspx)
More... (http://www.news-medical.net/news/20100820/SRI-and-Taiho-collaborate-to-advance-clinical-development-of-TAS-108-breast-cancer-program.aspx)